The FDA granted clearance to an investigational new drug application for EA-2351, a novel compound for the treatment of geographic atrophy, according to a press release from Endogena Therapeutics.
EA-2351 is designed to regenerate and restore photoreceptor function by activating retinal pigment epithelial cells. The clearance will allow for the first-in-human clinical investigation of EA-2351, which Endogena plans to begin in 2024.
The FDA previously granted fast track designation for EA-2353 in retinitis pigmentosa, with a clinical trial beginning in July 2022.
“We look forward to